Clinical Outcomes and Predictive Factors of Combination Treatment With Oral Doxycycline, Topical Calcineurin Inhibitor, and Pulsed Dye Laser in Erythematotelangiectatic Rosacea
- 10 February 2026
- journal article
- Published by Wiley in Lasers in Surgery and Medicine
- Vol. 58 (3) , 223-229
Abstract
Objective: Given that the therapeutic evidence for doxycycline in rosacea has predominantly been derived from studies on papulopustular rosacea (PPR), this study aimed to evaluate the efficacy and safety of combined oral doxycycline, topical calcineurin inhibitor (TCI), and pulsed dye laser (PDL) therapy in erythematotelangiectatic rosacea (ETR) and to identify clinical predictors of treatment response. Materials and Methods: Medical photographs of patients with ETR treated with oral doxycycline, TCI, and two subsequent PDL sessions were retrospectively reviewed. Erythema on the right cheek was quantitatively measured using computer‐aided image analysis. Results: Of the 79 included patients, 47 had the ETR subtype and 32 had the mixed ETR/PPR subtype. Erythema significantly improved after oral doxycycline and TCI treatment ( p < 0.001) and further PDL treatment ( p < 0.001). Particularly, in patients with moderate‐to‐severe ETR, background erythema improved to a level comparable to that observed in patients with mild ETR after treatment ( p = 0.307). Post‐treatment erythema did not differ by age ( p = 0.963) or Fitzpatrick skin type ( p = 0.277); however, it was significantly lower among males ( p = 0.008) and in patients without prior steroid treatment ( p = 0.046). No serious adverse events, including photosensitivity, were observed. Conclusion: Combined oral doxycycline, TCI, and PDL therapy is effective and safe for ETR, especially in patients with higher severity. Prompt diagnosis and avoidance of steroid misuse may improve treatment responses.Keywords
This publication has 45 references indexed in Scilit:
- Reproductive and hormonal factors and risk of incident rosacea among US White womenJournal of the American Academy of Dermatology, 2022
- A randomized phase 3b/4 study to evaluate concomitant use of topical ivermectin 1% cream and doxycycline 40-mg modified-release capsules, versus topical ivermectin 1% cream and placebo in the treatment of severe rosaceaJournal of the American Academy of Dermatology, 2020
- Treatment of Erythematotelangiectatic Rosacea With Pulsed‐Dye Laser and Oxymetazoline 1.0% Cream: A Retrospective StudyLasers in Surgery and Medicine, 2019
- Abnormal Glucocorticoid Synthesis in the Lesional Skin of Erythematotelangiectatic RosaceaJournal of Investigative Dermatology, 2019
- Standard classification and pathophysiology of rosacea: The 2017 update by the National Rosacea Society Expert CommitteeJournal of the American Academy of Dermatology, 2018
- Improved clinical outcome and biomarkers in adults with papulopustular rosacea treated with doxycycline modified-release capsules in a randomized trialJournal of the American Academy of Dermatology, 2016
- Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosaceaJournal of the American Academy of Dermatology, 2007
- A randomized, double-blind, placebo-controlled trial of the combined effect of doxycycline hyclate 20-mg tablets and metronidazole 0.75% topical lotion in the treatment of rosaceaJournal of the American Academy of Dermatology, 2005
- Pulsed dye laser treatment of rosacea improves erythema, symptomatology, and quality of lifeJournal of the American Academy of Dermatology, 2004
- Laser Treatment of Erythema and Telangiectasia Associated with RosaceaLasers in Medical Science, 2002